News | Cardiac Imaging | September 01, 2015

Pie Medical Imaging Recognized for Innovation in Quantitative Cardiovascular Software

Company receives European award for technology leadership from Frost & Sullivan

Pie Medical Imaging, Frost & Sullivan, technology leadership, CAAS, cardiovascular diagnostics

CAAS MRV is part of Pie Medical Imaging's suite of imaging solutions for quantitative cardiovascular diagnosis and treatment planning. - See more at: http://www.itnonline.com/content/pie-medical-imaging-recognized-innovation-quantitative-cardiovascular-software#sthash.lkTQkzwT.dpuf

September 1, 2015 — Based on its recent analysis of the cardiovascular image management market, Frost & Sullivan recognizes Pie Medical Imaging (PMI) with the 2015 European Frost & Sullivan Award for Technology Leadership. The Netherlands-based PMI has designed innovative and easy-to-use imaging solutions — its CAAS and 3mensio product lines — which deliver precise and reproducible quantitative results for cardiovascular diagnosis and treatment planning. By improving the quality of cardiovascular diagnostics and interventions, the software is effectually facilitating next-generation research on the efficacy of novel intervention methods.

Among existing imaging modalities, cardiovascular magnetic resonance imaging (CMR) plays a role of growing importance in the assessment of patients with heart failure (HF). Currently, it is difficult to study the myocardial perfusion status in HF due to left ventricular (LV) remodeling and wall thinning, coexistent scars and respiratory artefacts. There is an urgent need for state-of-the-art imaging modalities with software algorithms to diagnose cardiovascular diseases accurately and at an early stage. In response to this need, PMI developed CAAS MRV, a sophisticated software that provides quantitative analyses of cardiovascular magnetic resonance images.

Left and right ventricular analysis from CMR datasets and blood flow measurements from velocity-encoded MR will assist the medical specialist in selecting the best treatment options. For flow analysis, PMI offers CAAS MR Flow and recently released its highly innovative CAAS MR 4D Flow to complete its CMR analysis portfolio.

During interventional procedures, as performed in the catheterization laboratory under X-ray guidance, other analysis tools are required. "Unlike visual estimations of coronary artery dimensions, CAAS QCA automatically determines stenosis severity, which refines the visual estimate and provides objective and reproducible measurements of several important features of the coronary anatomy," said Frost & Sullivan Industry Analyst Darshana De. "To develop the CAAS platform further, PMI has more than 60 full-time R&D resources dedicated to developing and optimizing the advanced visualization and analysis software."

PMI is the market leader in cardiovascular analysis software for cardiology and radiology. Its CAAS and 3mensio brands offer a broad range of products for the analysis of X-ray, MRI, computed tomography (CT), optical coherence tomography (OCT) and intravascular ultrasound (IVUS) images. Its unique products provide:

  • Aortic regurgitation analysis based on X-ray angiography for use in aortic valve replacement procedures (CAAS A-valve);
  • Vessel analysis from MR datasets for research, including bifurcation analysis, vessel wall determination and plaque composition analysis (CAAS MRA);
  • Pre-op planning software for aortic valve, mitral valve and left atrial appendage interventions based on CT imaging (3mensio Structural Heart);
  • Abdominal aneurysm repair (EVAR) analysis software based on CT imaging (3mensio Vascular); and
  • 3-D coronary reconstruction and analysis from two X-ray projections (CAAS QCA3D).

PMI has close ties with research institutions in Europe, the United States, Japan and Australia. These partnerships include evaluation studies and co-development of products and solutions. It also works with core labs such as CRF, New York and Cardialysis in Rotterdam to study the efficacy of new treatment methods.

"PMI's CAAS Workstation is a stand-alone modular software product for the viewing and quantification of X-ray angiographic images and runs on a standard personal computer," noted De. "Its quantitative analyses results are based on semi-automatic contour detection forms and can be exported in various formats across different consoles, independent of the type of vendor acquisition equipment."

The CAAS Workstation offers segmentation of different cardiovascular structures, 3-D reconstruction of vessel segments based on two X-ray projections, as well as measurement and reporting tools. It aids in calculating the dimensions of cardiovascular structures, quantifying stenosis in coronary and peripheral vessels, the motion quantification of left and right ventricular walls, as well as stent visualization and dimension measurement.

For more information: www.piemedicalimaging.com

Related Content

 Medtronic Evolut TAVR Cleared in Canada for Both Bicuspid Valves in Intermediate or Greater Risk and for All Low Risk Patients for TAVR
News | Structural Heart | January 11, 2021
January 11, 2021 — Medtronic has received a new expanded indication from Health Canada for its Evolut Transcatheter A
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F Products + Features GmbH TricValve Transcatheter Bicval Valves System. The system uses two self-expanding valves in the vena cava for the treatment of patients with hemodynamically relevant tricuspid insufficiency without the need to touch the native tricuspid valve. #TTVR

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F Products + Features GmbH TricValve Transcatheter Bicval Valves System. The system uses two self-expanding valves in the vena cava for the treatment of patients with hemodynamically relevant tricuspid insufficiency without the need to touch the native tricuspid valve.

News | Structural Heart | January 06, 2021
January 6, 2021 — The U.S.
First Patient Treated With Harpoon Transcatheter Mitral Valve Repair Device in U.S. Trial. #TMVR
News | Structural Heart | December 29, 2020
December 29, 2020 — Edwards Lifesciences announced Dec.
Health Canada has approved the expanded use of the Edwards Lifesciences Sapien 3 and Sapien 3 Ultra transcatheter aortic valve replacement (TAVR) heart valves for the transfemoral treatment of patients diagnosed with severe symptomatic aortic stenosis who are at low risk for open-heart surgery. #TAVR #TAVI
News | Structural Heart | December 29, 2020
December 29, 2020 — Health Canada has approved the expanded use of the Edwards Lifesciences Sapien 3 and Sapien 3 Ult
An example of a 80-year-old TAVR patient planning CT scan from Northwestern Medicine's Central DuPage Hospital. This was used in a heart team meeting with the TAVR staff, including a cardiac surgeon and interventional cardiologist, to determine if this patient was eligable for TAVR, the best access routes to deliver the valve, device valve size needed, and to look for any potential anatomical issues so they can be planned for. 

An example of a 80-year-old TAVR patient planning CT scan from Northwestern Medicine's Central DuPage Hospital. This was used in a heart team meeting with the TAVR staff, including a cardiac surgeon and interventional cardiologist, to determine if this patient was eligible for TAVR, the best access routes to deliver the valve, device valve size needed, and to look for any potential anatomical issues so they can be planned for.

News | Structural Heart | September 02, 2020
September 2, 2020 — Northwestern Medicine Bluhm Cardiovascular Institute physicians recently completed their 2,000th
Neovasc Files CE Mark for Tiara TA Transapical Mitral Valve Replacement System. TMVR
News | Structural Heart | May 29, 2020
May 29, 2020 — Neovasc Inc., developer of a minimally invasive transcatheter mitral valve replacement (TMVR) technolo
Videos | Structural Heart | April 01, 2020
A review of the PARTNER 3 Low-Risk Trial with ...